Deepak Cyril D'Souza - Publications

Psychiatry Yale University School of Medicine, New Haven, CT 
Cannabis, THC, Schizophrenia

132 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Schindler EAD, Sewell RA, Gottschalk CH, Luddy C, Flynn LT, Lindsey H, Pittman BP, Cozzi NV, D'Souza DC. Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. PMID 33184743 DOI: 10.1007/s13311-020-00962-y  0.6
2020 Ranganathan M, D'Souza DC. Alterations in the Endocannabinoid System in Schizophrenia. Biological Psychiatry. 88: 675-677. PMID 33032694 DOI: 10.1016/j.biopsych.2020.08.019  0.6
2020 D'Souza DC, Radhakrishnan R, Naganawa M, Ganesh S, Nabulsi N, Najafzadeh S, Ropchan J, Ranganathan M, Cortes-Briones J, Huang Y, Carson RE, Skosnik P. Preliminary in vivo evidence of lower hippocampal synaptic density in cannabis use disorder. Molecular Psychiatry. PMID 32973170 DOI: 10.1038/s41380-020-00891-4  0.76
2020 Abdallah CG, Ahn KH, Averill LA, Nemati S, Averill CL, Fouda S, Ranganathan M, Morgan PT, D'Souza DC, Mathalon DH, Krystal JH, Driesen NR. A robust and reproducible connectome fingerprint of ketamine is highly associated with the connectomic signature of antidepressants. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 32967000 DOI: 10.1038/s41386-020-00864-9  0.6
2020 Schindler EAD, Schnakenberg Martin AM, Sewell RA, Ranganathan M, DeForest A, Pittman BP, Perrino A, D'Souza DC. In an exploratory randomized, double-blind, placebo-controlled, cross-over study, psychoactive doses of intravenous delta-9-tetrahydrocannabinol fail to produce antinociceptive effects in healthy human volunteers. Psychopharmacology. PMID 32632491 DOI: 10.1007/s00213-020-05595-9  0.6
2020 Beck K, Hindley G, Borgan F, Ginestet C, McCutcheon R, Brugger S, Driesen N, Ranganathan M, D'Souza DC, Taylor M, Krystal JH, Howes OD. Association of Ketamine With Psychiatric Symptoms and Implications for Its Therapeutic Use and for Understanding Schizophrenia: A Systematic Review and Meta-analysis. Jama Network Open. 3: e204693. PMID 32437573 DOI: 10.1001/jamanetworkopen.2020.4693  0.6
2020 Ganesh S, Cortes-Briones J, Ranganathan M, Radhakrishnan R, Skosnik PD, D'Souza DC. Psychosis-relevant effects of intravenous delta-9-tetrahydrocannabinol - A mega analysis of individual participant-data from human laboratory studies. The International Journal of Neuropsychopharmacology. PMID 32385508 DOI: 10.1093/ijnp/pyaa031  0.92
2020 Hindley G, Beck K, Borgan F, Ginestet CE, McCutcheon R, Kleinloog D, Ganesh S, Radhakrishnan R, D'Souza DC, Howes OD. Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis. The Lancet. Psychiatry. PMID 32197092 DOI: 10.1016/S2215-0366(20)30074-2  0.76
2020 Hu Y, Ranganathan M, Shu C, Liang X, Ganesh S, Osafo-Addo A, Yan C, Zhang X, Aouizerat BE, Krystal JH, D'Souza DC, Xu K. Single-cell Transcriptome Mapping Identifies Common and Cell-type Specific Genes Affected by Acute Delta9-tetrahydrocannabinol in Humans. Scientific Reports. 10: 3450. PMID 32103029 DOI: 10.1038/s41598-020-59827-1  0.6
2020 Abdallah CG, Averill LA, Gueorguieva R, Goktas S, Purohit P, Ranganathan M, Sherif M, Ahn KH, D'Souza DC, Formica R, Southwick SM, Duman RS, Sanacora G, Krystal JH. Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 32092760 DOI: 10.1038/s41386-020-0644-9  0.6
2019 Radhakrishnan R, Matuskey D, Nabulsi N, Gaiser E, Gallezot JD, Henry S, Planeta B, Lin SF, Ropchan J, Huang Y, Carson RE, D'Souza DC. In vivo 5-HT and 5-HT receptor availability in antipsychotic treated schizophrenia patients vs. unmedicated healthy humans measured with [C]GSK215083 PET. Psychiatry Research. Neuroimaging. 295: 111007. PMID 31760336 DOI: 10.1016/j.pscychresns.2019.111007  0.76
2019 D'Souza DC, Ganesh S, Cortes-Briones J, Campbell MH, Emmanuel MK. Characterizing psychosis-relevant phenomena and cognitive function in a unique population with isolated, chronic and very heavy cannabis exposure. Psychological Medicine. 1-8. PMID 31615592 DOI: 10.1017/S0033291719002721  0.44
2019 Ranganathan M, De Aquino JP, Cortes-Briones JA, Radhakrishnan R, Pittman B, Bhakta S, D'Souza DC. Highs and lows of cannabinoid-dopamine interactions: effects of genetic variability and pharmacological modulation of catechol-O-methyl transferase on the acute response to delta-9-tetrahydrocannabinol in humans. Psychopharmacology. PMID 31187152 DOI: 10.1007/s00213-019-05273-5  0.76
2019 Radhakrishnan R, Ranganathan M, D'Souza DC. Medical Marijuana: What Physicians Need to Know. The Journal of Clinical Psychiatry. 80. PMID 31087827 DOI: 10.4088/JCP.18ac12537  0.76
2019 Gupta S, De Aquino JP, D'Souza DC, Ranganathan M. Effects of haloperidol on the delta-9-tetrahydrocannabinol response in humans: a responder analysis. Psychopharmacology. PMID 30919005 DOI: 10.1007/s00213-019-05235-x  0.6
2019 Orr C, Spechler P, Cao Z, Albaugh M, Chaarani B, Mackey S, D'Souza D, Allgaier N, Banaschewski T, Bokde ALW, Bromberg U, Büchel C, Burke Quinlan E, Conrod P, Desrivières S, et al. Grey Matter Volume Differences Associated with Extremely Low Levels of Cannabis Use in Adolescence. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. PMID 30643026 DOI: 10.1523/JNEUROSCI.3375-17.2018  0.76
2018 D'Souza DC, Cortes-Briones J, Creatura G, Bluez G, Thurnauer H, Deaso E, Bielen K, Surti T, Radhakrishnan R, Gupta A, Gupta S, Cahill J, Sherif MA, Makriyannis A, Morgan PT, et al. Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial. The Lancet. Psychiatry. PMID 30528676 DOI: 10.1016/S2215-0366(18)30427-9  0.92
2018 Boggs DL, Cortes-Briones JA, Surti T, Luddy C, Ranganathan M, Cahill JD, Sewell AR, D'Souza DC, Skosnik PD. The dose-dependent psychomotor effects of intravenous delta-9-tetrahydrocannabinol (Δ-THC) in humans. Journal of Psychopharmacology (Oxford, England). 269881118799953. PMID 30255720 DOI: 10.1177/0269881118799953  0.92
2018 De Aquino JP, Sherif M, Radhakrishnan R, Cahill JD, Ranganathan M, D'Souza DC. The Psychiatric Consequences of Cannabinoids. Clinical Therapeutics. PMID 29678279 DOI: 10.1016/j.clinthera.2018.03.013  0.76
2018 Radhakrishnan R, Nabulsi N, Gaiser E, Gallezot JD, Henry S, Planeta B, Lin SF, Ropchan J, Williams W, Morris E, D'Souza DC, Huang Y, Carson RE, Matuskey D. Age-related change in 5-HT6 receptor availability in healthy male volunteers measured withC-GSK215083 PET. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 29626125 DOI: 10.2967/jnumed.117.206516  0.76
2018 Boggs DL, Surti T, Gupta A, Gupta S, Niciu M, Pittman B, Schnakenberg Martin AM, Thurnauer H, Davies A, D'Souza DC, Ranganathan M. The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial. Psychopharmacology. PMID 29619533 DOI: 10.1007/s00213-018-4885-9  0.6
2018 Skosnik PD, Hajós M, Cortes-Briones JA, Edwards CR, Pittman BP, Hoffmann WE, Sewell AR, D'Souza DC, Ranganathan M. Cannabinoid receptor-mediated disruption of sensory gating and neural oscillations: A translational study in rats and humans. Neuropharmacology. PMID 29604295 DOI: 10.1016/j.neuropharm.2018.03.036  0.92
2018 D'Souza DC, Carson RE, Driesen N, Johannesen J, Ranganathan M, Krystal JH. Dose-Related Target Occupancy and Effects on Circuitry, Behavior, and Neuroplasticity of the Glycine Transporter-1 Inhibitor PF-03463275 in Healthy and Schizophrenia Subjects. Biological Psychiatry. PMID 29499855 DOI: 10.1016/j.biopsych.2017.12.019  0.6
2017 Skosnik PD, D'Souza DC. Opposing Effects of Cannabis Use on Electroencephalographic Measures of Auditory Repetition Suppression in Schizophrenia and Healthy Controls. Biological Psychiatry. Cognitive Neuroscience and Neuroimaging. 2: 209-211. PMID 29528290 DOI: 10.1016/j.bpsc.2017.03.004  0.92
2017 Hamilton HK, D'Souza DC, Ford JM, Roach BJ, Kort NS, Ahn KH, Bhakta S, Ranganathan M, Mathalon DH. Interactive effects of an N-methyl-d-aspartate receptor antagonist and a nicotinic acetylcholine receptor agonist on mismatch negativity: Implications for schizophrenia. Schizophrenia Research. PMID 28711472 DOI: 10.1016/j.schres.2017.06.040  0.6
2017 Ranganathan M, Radhakrishnan R, Addy PH, Schnakenberg A, Williams A, Carbuto M, Elander J, Pittman B, Andrew Sewell R, Skosnik PD, D'Souza DC. Tetrahydrocannabinol (THC) impairs encoding but not retrieval of verbal information. Progress in Neuro-Psychopharmacology & Biological Psychiatry. PMID 28642081 DOI: 10.1016/j.pnpbp.2017.06.019  0.92
2017 Boggs DL, Surti TS, Esterlis I, Pittman B, Cosgrove K, Sewell RA, Ranganathan M, D'Souza DC. Minimal effects of prolonged smoking abstinence or resumption on cognitive performance challenge the "self-medication" hypothesis in schizophrenia. Schizophrenia Research. PMID 28392208 DOI: 10.1016/j.schres.2017.03.047  0.6
2017 Ranganathan M, DeMartinis N, Huguenel B, Gaudreault F, Bednar MM, Shaffer CL, Gupta S, Cahill J, Sherif MA, Mancuso J, Zumpano L, D'Souza DC. Attenuation of ketamine-induced impairment in verbal learning and memory in healthy volunteers by the AMPA receptor potentiator PF-04958242. Molecular Psychiatry. PMID 28242871 DOI: 10.1038/mp.2017.6  0.6
2016 D'Souza DC, Cortes-Briones JA, Ranganathan M, Thurnauer H, Creatura G, Surti T, Planeta B, Neumeister A, Pittman B, Normandin MD, Kapinos M, Ropchan J, Huang Y, Carson RE, Skosnik PD. Rapid Changes in Cannabinoid 1 Receptor Availability in Cannabis-Dependent Male Subjects After Abstinence From Cannabis. Biological Psychiatry. Cognitive Neuroscience and Neuroimaging. 1: 60-67. PMID 29560896 DOI: 10.1016/j.bpsc.2015.09.008  0.92
2016 D Souza DC, Radhakrishnan R, Sherif M, Cortes-Briones J, Cahill J, Gupta S, Skosnik PD, Ranganathan M. Cannabinoids and Psychosis. Current Pharmaceutical Design. PMID 27568729  0.44
2016 Wilkinson ST, Radhakrishnan R, D'Souza DC. A Systematic Review of the Evidence for Medical Marijuana in Psychiatric Indications. The Journal of Clinical Psychiatry. 77: 1050-64. PMID 27561138 DOI: 10.4088/JCP.15r10036  0.92
2016 DeWorsop D, Creatura G, Bluez G, Thurnauer H, Forselius-Bielen K, Ranganathan M, Deaso E, Bhat JA, D'Souza DC. Feasibility and success of cell-phone assisted remote observation of medication adherence (CAROMA) in clinical trials. Drug and Alcohol Dependence. PMID 27068252 DOI: 10.1016/j.drugalcdep.2016.02.045  0.92
2016 Sherif M, Radhakrishnan R, D'Souza DC, Ranganathan M. Human Laboratory Studies on Cannabinoids and Psychosis. Biological Psychiatry. 79: 526-38. PMID 26970363 DOI: 10.1016/j.biopsych.2016.01.011  0.32
2016 Ranganathan M, Skosnik PD, D'Souza DC. Marijuana and Madness: Associations Between Cannabinoids and Psychosis. Biological Psychiatry. 79: 511-3. PMID 26970361 DOI: 10.1016/j.biopsych.2016.02.007  0.32
2016 D'Souza DC, Cortes-Briones JA, Ranganathan M, Thurnauer H, Creatura G, Surti T, Planeta B, Neumeister A, Pittman B, Normandin M, Kapinos M, Ropchan J, Huang Y, Carson RE, Skosnik PD. Rapid Changes in CB1 Receptor Availability in Cannabis Dependent Males after Abstinence from Cannabis. Biological Psychiatry : Cognitive Neuroscience and Neuroimaging. 1: 60-67. PMID 26858993 DOI: 10.1016/j.bpsc.2015.09.008  0.92
2015 Gupta S, Ranganathan M, D'Souza DC. The early identification of psychosis: can lessons be learnt from cardiac stress testing? Psychopharmacology. PMID 26566609 DOI: 10.1007/s00213-015-4143-3  0.44
2015 Wilkinson ST, Yarnell S, Radhakrishnan R, Ball SA, D'Souza DC. Marijuana Legalization: Impact on Physicians and Public Health. Annual Review of Medicine. PMID 26515984 DOI: 10.1146/annurev-med-050214-013454  0.32
2015 Ranganathan M, Cortes-Briones J, Radhakrishnan R, Thurnauer H, Planeta B, Skosnik P, Gao H, Labaree D, Neumeister A, Pittman B, Surti T, Huang Y, Carson RE, D'Souza DC. Reduced Brain Cannabinoid Receptor Availability In Schizophrenia. Biological Psychiatry. PMID 26432420 DOI: 10.1016/j.biopsych.2015.08.021  0.92
2015 D'Souza DC, Ranganathan M. Medical Marijuana: Is the Cart Before the Horse? Jama. 313: 2431-2. PMID 26103026 DOI: 10.1001/jama.2015.6407  0.92
2015 Wilkinson ST, van Schalkwyk GI, Davidson L, D'Souza DC. The Formation of Marijuana Risk Perception in a Population of Substance Abusing Patients. The Psychiatric Quarterly. PMID 25982082 DOI: 10.1007/s11126-015-9369-z  0.76
2015 Ahn KH, Sewell A, Elander J, Pittman B, Ranganathan M, Gunduz-Bruce H, Krystal J, D'Souza DC. Role of GABA Deficit in Sensitivity to the Psychotomimetic Effects of Amphetamine. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 25953357 DOI: 10.1038/npp.2015.132  0.6
2015 Cortes-Briones JA, Cahill JD, Skosnik PD, Mathalon DH, Williams A, Sewell RA, Roach BJ, Ford JM, Ranganathan M, D'Souza DC. The Psychosis-like Effects of Δ(9)-Tetrahydrocannabinol Are Associated with Increased Cortical Noise in Healthy Humans. Biological Psychiatry. PMID 25913109 DOI: 10.1016/j.biopsych.2015.03.023  0.92
2015 Radhakrishnan R, Skosnik PD, Cortes-Briones J, Sewell RA, Carbuto M, Schnakenberg A, Cahill J, Bois F, Gunduz-Bruce H, Pittman B, Ranganathan M, D'Souza DC. GABA Deficits Enhance the Psychotomimetic Effects of Δ(9)-THC. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 40: 2047-56. PMID 25728472 DOI: 10.1038/npp.2015.58  0.92
2015 Cortes-Briones J, Skosnik PD, Mathalon D, Cahill J, Pittman B, Williams A, Sewell RA, Ranganathan M, Roach B, Ford J, D'Souza DC. Δ(9)-THC Disrupts Gamma (γ)-Band Neural Oscillations in Humans. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 40: 2124-34. PMID 25709097 DOI: 10.1038/npp.2015.53  0.32
2015 Slifstein M, van de Giessen E, Van Snellenberg J, Thompson JL, Narendran R, Gil R, Hackett E, Girgis R, Ojeil N, Moore H, D'Souza D, Malison RT, Huang Y, Lim K, Nabulsi N, et al. Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study. Jama Psychiatry. 72: 316-24. PMID 25651194 DOI: 10.1001/jamapsychiatry.2014.2414  0.92
2015 Cortes-Briones JA, Cahill JD, Ranganathan M, Sewell RA, D'Souza DC, Skosnik PD. Testing differences in the activity of event-related potential sources: important implications for clinical researchers. Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology. 126: 215-8. PMID 24840905 DOI: 10.1016/j.clinph.2014.04.008  0.92
2015 Ahn KH, Sewell A, Elander J, Pittman B, Ranganathan M, Gunduz-Bruce H, Krystal J, D'Souza DC. Role of GABA Deficit in Sensitivity to the Psychotomimetic Effects of Amphetamine Neuropsychopharmacology. DOI: 10.1038/npp.2015.132  0.32
2014 Wilkinson ST, Radhakrishnan R, D'Souza DC. Impact of Cannabis Use on the Development of Psychotic Disorders. Current Addiction Reports. 1: 115-128. PMID 25767748 DOI: 10.1007/s40429-014-0018-7  0.76
2014 Wilkinson ST, D'Souza DC. Medicalization of marijuana--reply. Jama. 312: 1931-2. PMID 25387198 DOI: 10.1001/jama.2014.12569  0.92
2014 Skosnik PD, Krishnan GP, D'Souza DC, Hetrick WP, O'Donnell BF. Disrupted gamma-band neural oscillations during coherent motion perception in heavy cannabis users. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 39: 3087-99. PMID 24990428 DOI: 10.1038/npp.2014.166  0.92
2014 Radhakrishnan R, Wilkinson ST, D'Souza DC. Gone to Pot - A Review of the Association between Cannabis and Psychosis. Frontiers in Psychiatry. 5: 54. PMID 24904437 DOI: 10.3389/fpsyt.2014.00054  0.92
2014 Wilkinson ST, D'Souza DC. Problems with the medicalization of marijuana. Jama. 311: 2377-8. PMID 24845238 DOI: 10.1001/jama.2014.6175  0.92
2014 Mathalon DH, Ahn KH, Perry EB, Cho HS, Roach BJ, Blais RK, Bhakta S, Ranganathan M, Ford JM, D'Souza DC. Effects of nicotine on the neurophysiological and behavioral effects of ketamine in humans. Frontiers in Psychiatry. 5: 3. PMID 24478731 DOI: 10.3389/fpsyt.2014.00003  0.92
2014 Ranganathan M, Sewell RA, Carbuto M, Elander J, Schnakenberg A, Radhakrishnan R, Pittman B, D'Souza DC. Effects of Δ9-tetrahydrocannabinol in individuals with a familial vulnerability to alcoholism. Psychopharmacology. 231: 2385-93. PMID 24424782 DOI: 10.1007/s00213-013-3402-4  0.92
2014 Leatherman SM, Liang MH, Krystal JH, Lew RA, Valley D, Thwin SS, Rosenheck RA. Differences in treatment effect among clinical subgroups in a randomized clinical trial of long-acting injectable risperidone and oral antipsychotics in unstable chronic schizophrenia. The Journal of Nervous and Mental Disease. 202: 13-7. PMID 24375206 DOI: 10.1097/NMD.0000000000000069  0.92
2014 Esterlis I, Ranganathan M, Bois F, Pittman B, Picciotto MR, Shearer L, Anticevic A, Carlson J, Niciu MJ, Cosgrove KP, D'Souza DC. In vivo evidence for β2 nicotinic acetylcholine receptor subunit upregulation in smokers as compared with nonsmokers with schizophrenia. Biological Psychiatry. 76: 495-502. PMID 24360979 DOI: 10.1016/j.biopsych.2013.11.001  0.92
2014 Boggs DL, Carlson J, Cortes-Briones J, Krystal JH, D'Souza DC. Going up in smoke? A review of nAChRs-based treatment strategies for improving cognition in schizophrenia. Current Pharmaceutical Design. 20: 5077-92. PMID 24345265 DOI: 10.2174/1381612819666131216121019  0.92
2013 Boggs DL, Ranganathan M, Boggs AA, Bihday CM, Peluse BE, D'Souza DC. Treatment of hyperprolactinemia and gynecomastia with adjunctive aripiprazole in 2 men receiving long-acting injectable antipsychotics. The Primary Care Companion For Cns Disorders. 15. PMID 24392257 DOI: 10.4088/PCC.13l01519  0.92
2013 Boggs DL, Ranganathan M, Sewell RA, Madonick S, D'Souza DC. Pilot study of intravenous nicotine effects on cognitive performance in schizophrenia. Schizophrenia Research. 150: 323-4. PMID 23953216 DOI: 10.1016/j.schres.2013.07.045  0.92
2013 Driesen NR, McCarthy G, Bhagwagar Z, Bloch MH, Calhoun VD, D'Souza DC, Gueorguieva R, He G, Leung HC, Ramani R, Anticevic A, Suckow RF, Morgan PT, Krystal JH. The impact of NMDA receptor blockade on human working memory-related prefrontal function and connectivity. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 38: 2613-22. PMID 23856634 DOI: 10.1038/npp.2013.170  0.92
2013 Spaderna M, Addy PH, D'Souza DC. Spicing things up: synthetic cannabinoids. Psychopharmacology. 228: 525-40. PMID 23836028 DOI: 10.1007/s00213-013-3188-4  0.92
2013 Esterlis I, Hannestad JO, Perkins E, Bois F, D'Souza DC, Tyndale RF, Seibyl JP, Hatsukami DM, Cosgrove KP, O'Malley SS. Effect of a nicotine vaccine on nicotine binding to β2*-nicotinic acetylcholine receptors in vivo in human tobacco smokers. The American Journal of Psychiatry. 170: 399-407. PMID 23429725 DOI: 10.1176/appi.ajp.2012.12060793  0.92
2013 Driesen NR, McCarthy G, Bhagwagar Z, Bloch M, Calhoun V, D'Souza DC, Gueorguieva R, He G, Ramachandran R, Suckow RF, Anticevic A, Morgan PT, Krystal JH. Relationship of resting brain hyperconnectivity and schizophrenia-like symptoms produced by the NMDA receptor antagonist ketamine in humans. Molecular Psychiatry. 18: 1199-204. PMID 23337947 DOI: 10.1038/mp.2012.194  0.92
2013 Gunduz-Bruce H, Oliver S, Gueorguieva R, Forselius-Bielen K, D'Souza DC, Zimolo Z, Tek C, Kaliora S, Ray S, Petrides G. Efficacy of pimozide augmentation for clozapine partial responders with schizophrenia. Schizophrenia Research. 143: 344-7. PMID 23219861 DOI: 10.1016/j.schres.2012.11.008  0.92
2013 Sewell RA, Schnakenberg A, Elander J, Radhakrishnan R, Williams A, Skosnik PD, Pittman B, Ranganathan M, D'Souza DC. Acute effects of THC on time perception in frequent and infrequent cannabis users. Psychopharmacology. 226: 401-13. PMID 23179965 DOI: 10.1007/s00213-012-2915-6  0.92
2013 D'Souza DC, Radhakrishnan R, Perry E, Bhakta S, Singh NM, Yadav R, Abi-Saab D, Pittman B, Chaturvedi SK, Sharma MP, Bell M, Andrade C. Feasibility, safety, and efficacy of the combination of D-serine and computerized cognitive retraining in schizophrenia: an international collaborative pilot study. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 38: 492-503. PMID 23093223 DOI: 10.1038/npp.2012.208  0.92
2013 Woods SW, Walsh BC, Hawkins KA, Miller TJ, Saksa JR, D'Souza DC, Pearlson GD, Javitt DC, McGlashan TH, Krystal JH. Glycine treatment of the risk syndrome for psychosis: report of two pilot studies. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 23: 931-40. PMID 23089076 DOI: 10.1016/j.euroneuro.2012.09.008  0.92
2013 Radhakrishnan R, Addy PH, Sewell RA, Skosnik PD, Ranganathan M, D'Souza DC. Cannabis, Cannabinoids, and the Association with Psychosis The Effects of Drug Abuse On the Human Nervous System. 423-474. DOI: 10.1016/B978-0-12-418679-8.00014-9  0.92
2012 Ranganathan M, Schnakenberg A, Skosnik PD, Cohen BM, Pittman B, Sewell RA, D'Souza DC. Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the κ opioid agonist Salvinorin A in humans. Biological Psychiatry. 72: 871-9. PMID 22817868 DOI: 10.1016/j.biopsych.2012.06.012  0.92
2012 D'Souza DC, Ahn K, Bhakta S, Elander J, Singh N, Nadim H, Jatlow P, Suckow RF, Pittman B, Ranganathan M. Nicotine fails to attenuate ketamine-induced cognitive deficits and negative and positive symptoms in humans: implications for schizophrenia. Biological Psychiatry. 72: 785-94. PMID 22717030 DOI: 10.1016/j.biopsych.2012.05.009  0.92
2012 Skosnik PD, D'Souza DC, Steinmetz AB, Edwards CR, Vollmer JM, Hetrick WP, O'Donnell BF. The effect of chronic cannabinoids on broadband EEG neural oscillations in humans. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 37: 2184-93. PMID 22713908 DOI: 10.1038/npp.2012.65  0.92
2012 Keefe RS, Vinogradov S, Medalia A, Buckley PF, Caroff SN, D'Souza DC, Harvey PD, Graham KA, Hamer RM, Marder SM, Miller DD, Olson SJ, Patel JK, Velligan D, Walker TM, et al. Feasibility and pilot efficacy results from the multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) randomized controlled trial. The Journal of Clinical Psychiatry. 73: 1016-22. PMID 22687548 DOI: 10.4088/JCP.11m07100  0.92
2012 Skosnik PD, Ranganathan M, D'Souza DC. Cannabinoids, working memory, and schizophrenia. Biological Psychiatry. 71: 662-3. PMID 22449262 DOI: 10.1016/j.biopsych.2012.02.028  0.92
2012 D'Souza DC, Fridberg DJ, Skosnik PD, Williams A, Roach B, Singh N, Carbuto M, Elander J, Schnakenberg A, Pittman B, Sewell RA, Ranganathan M, Mathalon D. Dose-related modulation of event-related potentials to novel and target stimuli by intravenous Δ⁹-THC in humans. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 37: 1632-46. PMID 22334121 DOI: 10.1038/npp.2012.8  0.92
2012 Ranganathan M, Carbuto M, Braley G, Elander J, Perry E, Pittman B, Radhakrishnan R, Sewell RA, D'Souza DC. Naltrexone does not attenuate the effects of intravenous Δ9-tetrahydrocannabinol in healthy humans. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 15: 1251-64. PMID 22243563 DOI: 10.1017/S1461145711001830  0.92
2012 D'Souza DC, Esterlis I, Carbuto M, Krasenics M, Seibyl J, Bois F, Pittman B, Ranganathan M, Cosgrove K, Staley J. Lower ß2*-nicotinic acetylcholine receptor availability in smokers with schizophrenia. The American Journal of Psychiatry. 169: 326-34. PMID 22193533 DOI: 10.1176/appi.ajp.2011.11020189  0.92
2012 Ralevski E, Perry EB, D'Souza DC, Bufis V, Elander J, Limoncelli D, Vendetti M, Dean E, Cooper TB, McKee S, Petrakis I. Preliminary findings on the interactive effects of IV ethanol and IV nicotine on human behavior and cognition: a laboratory study. Nicotine & Tobacco Research : Official Journal of the Society For Research On Nicotine and Tobacco. 14: 596-606. PMID 22180582 DOI: 10.1093/ntr/ntr258  0.92
2012 D'Souza DC, Singh N, Elander J, Carbuto M, Pittman B, Udo de Haes J, Sjogren M, Peeters P, Ranganathan M, Schipper J. Glycine transporter inhibitor attenuates the psychotomimetic effects of ketamine in healthy males: preliminary evidence. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 37: 1036-46. PMID 22113087 DOI: 10.1038/npp.2011.295  0.92
2012 Gunduz-Bruce H, Reinhart RM, Roach BJ, Gueorguieva R, Oliver S, D'Souza DC, Ford JM, Krystal JH, Mathalon DH. Glutamatergic modulation of auditory information processing in the human brain. Biological Psychiatry. 71: 969-77. PMID 22036036 DOI: 10.1016/j.biopsych.2011.09.031  0.92
2012 Carbuto M, Sewell RA, Williams A, Forselius-Bielen K, Braley G, Elander J, Pittman B, Schnakenberg A, Bhakta S, Perry E, Ranganathan M, D'Souza DC. The safety of studies with intravenous Δ⁹-tetrahydrocannabinol in humans, with case histories. Psychopharmacology. 219: 885-96. PMID 21845389 DOI: 10.1007/s00213-011-2417-y  0.92
2011 Krystal JH, Petrakis IL, Limoncelli D, Nappi SK, Trevisan L, Pittman B, D'Souza DC, Suckow RF. Characterization of the interactive effects of glycine and D-cycloserine in men: further evidence for enhanced NMDA receptor function associated with human alcohol dependence. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 36: 701-10. PMID 21124304 DOI: 10.1038/npp.2010.203  0.44
2011 Ahn K, Gil R, Seibyl J, Sewell RA, D'Souza DC. Probing GABA receptor function in schizophrenia with iomazenil. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 36: 677-83. PMID 21068719 DOI: 10.1038/npp.2010.198  0.92
2010 Sewell RA, Perry EB, Karper LP, Bell MD, Lysaker P, Goulet JL, Brenner L, Erdos J, d'Souza DC, Seibyl JP, Krystal JH. Clinical significance of neurological soft signs in schizophrenia: factor analysis of the Neurological Evaluation Scale. Schizophrenia Research. 124: 1-12. PMID 20855185 DOI: 10.1016/j.schres.2010.08.036  0.92
2010 Kane JM, D'Souza DC, Patkar AA, Youakim JM, Tiller JM, Yang R, Keefe RS. Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study. The Journal of Clinical Psychiatry. 71: 1475-81. PMID 20816042 DOI: 10.4088/JCP.09m05950gry  0.92
2010 Sewell RA, Skosnik PD, Garcia-Sosa I, Ranganathan M, D'Souza DC. [Behavioral, cognitive and psychophysiological effects of cannabinoids: relevance to psychosis and schizophrenia]. Revista Brasileira De Psiquiatria (SãO Paulo, Brazil : 1999). 32: S15-30. PMID 20512267  0.92
2010 Corlett PR, D'Souza DC, Krystal JH. Capgras syndrome induced by ketamine in a healthy subject. Biological Psychiatry. 68: e1-2. PMID 20385373 DOI: 10.1016/j.biopsych.2010.02.015  0.92
2010 Krystal JH, Tolin DF, Sanacora G, Castner SA, Williams GV, Aikins DE, Hoffman RE, D'Souza DC. Neuroplasticity as a target of the pharmacotherapy of anxiety disorders, mood disorders and schizophrenia | Neuroplastyczność jako cel dla farmakoterapii zaburzeń lȩkowych, zaburzeń nastroju i schizofrenii Wiadomosci Psychiatryczne. 13: 163-173.  0.92
2009 Curran HV, D'Souza DC, Robbins TW, Fletcher P. Modelling psychosis. Psychopharmacology. 206: 513-4. PMID 19756521 DOI: 10.1007/s00213-009-1663-8  0.92
2009 D'Souza DC, Sewell RA, Ranganathan M. Cannabis and psychosis/schizophrenia: human studies. European Archives of Psychiatry and Clinical Neuroscience. 259: 413-31. PMID 19609589 DOI: 10.1007/s00406-009-0024-2  0.92
2009 Krystal JH, Tolin DF, Sanacora G, Castner SA, Williams GV, Aikins DE, Hoffman RE, D'Souza DC. Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia. Drug Discovery Today. 14: 690-7. PMID 19460458 DOI: 10.1016/j.drudis.2009.05.002  0.92
2009 Sewell RA, Ranganathan M, D'Souza DC. Cannabinoids and psychosis. International Review of Psychiatry (Abingdon, England). 21: 152-62. PMID 19367509 DOI: 10.1080/09540260902782802  0.92
2009 Ranganathan M, Braley G, Pittman B, Cooper T, Perry E, Krystal J, D'Souza DC. The effects of cannabinoids on serum cortisol and prolactin in humans. Psychopharmacology. 203: 737-44. PMID 19083209 DOI: 10.1007/s00213-008-1422-2  0.92
2009 D'Souza DC, Pittman B, Perry E, Simen A. Preliminary evidence of cannabinoid effects on brain-derived neurotrophic factor (BDNF) levels in humans. Psychopharmacology. 202: 569-78. PMID 18807247 DOI: 10.1007/s00213-008-1333-2  0.92
2008 D'Souza DC, Braley G, Blaise R, Vendetti M, Oliver S, Pittman B, Ranganathan M, Bhakta S, Zimolo Z, Cooper T, Perry E. Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Delta-9-tetrahydrocannabinol in humans. Psychopharmacology. 198: 587-603. PMID 18228005 DOI: 10.1007/s00213-007-1042-2  0.44
2008 D'Souza DC, Ranganathan M, Braley G, Gueorguieva R, Zimolo Z, Cooper T, Perry E, Krystal J. Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 33: 2505-16. PMID 18185500 DOI: 10.1038/sj.npp.1301643  0.44
2008 Trevisan L, Petrakis IL, Pittman B, Gueorguieva R, D'Souza DC, Perry E, Limoncelli D, Krystal JH. Absence of significant interactive effects of high-dose D-cycloserine and ethanol in healthy human subjects: preliminary insights into ethanol actions at the glycine B site of NMDA glutamate receptors. Alcoholism, Clinical and Experimental Research. 32: 36-42. PMID 18028532 DOI: 10.1111/j.1530-0277.2007.00543.x  0.92
2007 Perry EB, Cramer JA, Cho HS, Petrakis IL, Karper LP, Genovese A, O'Donnell E, Krystal JH, D'Souza DC. Psychiatric safety of ketamine in psychopharmacology research. Psychopharmacology. 192: 253-60. PMID 17458544 DOI: 10.1007/s00213-007-0706-2  0.92
2007 D'Souza DC. Cannabinoids and psychosis. International Review of Neurobiology. 78: 289-326. PMID 17349865 DOI: 10.1016/S0074-7742(06)78010-2  0.92
2006 Ranganathan M, D'Souza DC. The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology. 188: 425-44. PMID 17019571 DOI: 10.1007/s00213-006-0508-y  0.44
2006 D'Souza DC, Gil RB, Madonick S, Perry EB, Forselius-Bielen K, Braley G, Donahue L, Tellioglu T, Zimolo Z, Gueorguieva R, Krystal JH. Enhanced sensitivity to the euphoric effects of alcohol in schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 31: 2767-75. PMID 16985503 DOI: 10.1038/sj.npp.1301207  0.36
2006 Morgan CJ, Perry EB, Cho HS, Krystal JH, D'Souza DC. Greater vulnerability to the amnestic effects of ketamine in males. Psychopharmacology. 187: 405-14. PMID 16896964 DOI: 10.1007/s00213-006-0409-0  0.92
2006 Srihari VH, Lee TS, Rohrbaugh RM, D'Souza DC. Revisiting cycloid psychosis: a case of an acute, transient and recurring psychotic disorder. Schizophrenia Research. 82: 261-4. PMID 16442782 DOI: 10.1016/j.schres.2005.11.022  0.92
2006 Krystal JH, Madonick S, Perry E, Gueorguieva R, Brush L, Wray Y, Belger A, D'Souza DC. Potentiation of low dose ketamine effects by naltrexone: potential implications for the pharmacotherapy of alcoholism. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 31: 1793-800. PMID 16395307 DOI: 10.1038/sj.npp.1300994  0.92
2006 D'Souza DC, Gil RB, Zuzarte E, MacDougall LM, Donahue L, Ebersole JS, Boutros NN, Cooper T, Seibyl J, Krystal JH. gamma-Aminobutyric acid-serotonin interactions in healthy men: implications for network models of psychosis and dissociation. Biological Psychiatry. 59: 128-37. PMID 16140281 DOI: 10.1016/j.biopsych.2005.06.020  0.92
2006 D'Souza DC, Krystal JH. Glutamatergic function in the pathophysiology and treatment of psychiatric disorders Primary Psychiatry. 13: 36-37.  0.92
2006 Malik AR, D'Souza DC. Gone to pot: The association between cannabis and psychosis Psychiatric Times. 23: 28-29.  0.92
2005 D'Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, Gueorguieva R, Cooper TB, Krystal JH. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biological Psychiatry. 57: 594-608. PMID 15780846 DOI: 10.1016/j.biopsych.2004.12.006  0.92
2005 Cho HS, D'Souza DC, Gueorguieva R, Perry EB, Madonick S, Karper LP, Abi-Dargham A, Belger A, Abi-Saab W, Lipschitz D, Bennet A, Seibyl JP, Krystal JH. Absence of behavioral sensitization in healthy human subjects following repeated exposure to ketamine. Psychopharmacology. 179: 136-43. PMID 15682309 DOI: 10.1007/s00213-004-2066-5  0.92
2005 Krystal JH, Abi-Saab W, Perry E, D'Souza DC, Liu N, Gueorguieva R, McDougall L, Hunsberger T, Belger A, Levine L, Breier A. Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology. 179: 303-9. PMID 15309376 DOI: 10.1007/s00213-004-1982-8  0.92
2004 D'Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT, Braley G, Gueorguieva R, Krystal JH. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 29: 1558-72. PMID 15173844 DOI: 10.1038/sj.npp.1300496  0.92
2004 Jacobsen LK, D'Souza DC, Mencl WE, Pugh KR, Skudlarski P, Krystal JH. Nicotine effects on brain function and functional connectivity in schizophrenia. Biological Psychiatry. 55: 850-8. PMID 15050867 DOI: 10.1016/j.biopsych.2003.12.023  0.92
2004 Perry EB, Gil R, Miles D, Brenner L, MacDougall L, Johnson R, Degen K, Gueorguieva R, Petrakis IL, Krystal JH, D'Souza DC. Mazindol augmentation of antipsychotic treatment for schizophrenic patients with comorbid cocaine abuse or dependence: A preliminary double-blind, randomized, placebo-controlled trial Journal of Dual Diagnosis. 1: 37-47. DOI: 10.1300/J374v01n01_04  0.92
2003 Krystal JH, Petrakis IL, Krupitsky E, Schutz C, Trevisan L, D'Souza DC. NMDA receptor antagonism and the ethanol intoxication signal: from alcoholism risk to pharmacotherapy. Annals of the New York Academy of Sciences. 1003: 176-84. PMID 14684445 DOI: 10.1196/annals.1300.010  0.92
2003 Krystal JH, D'Souza DC, Mathalon D, Perry E, Belger A, Hoffman R. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology. 169: 215-33. PMID 12955285 DOI: 10.1007/s00213-003-1582-z  0.92
2003 Krystal JH, Petrakis IL, Limoncelli D, Webb E, Gueorgueva R, D'Souza DC, Boutros NN, Trevisan L, Charney DS. Altered NMDA glutamate receptor antagonist response in recovering ethanol-dependent patients. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 28: 2020-8. PMID 12888778 DOI: 10.1038/sj.npp.1300252  0.92
2003 Krystal JH, Petrakis IL, Mason G, Trevisan L, D'Souza DC. N-methyl-D-aspartate glutamate receptors and alcoholism: reward, dependence, treatment, and vulnerability. Pharmacology & Therapeutics. 99: 79-94. PMID 12804700 DOI: 10.1016/S0163-7258(03)00054-8  0.92
2001 Warner MD, Walker AM, D'Souza DC, Lee D, Nasseri D, Peabody CA. Lower prolactin bioactivity in unmedicated schizophrenic patients. Psychiatry Research. 102: 249-54. PMID 11440775 DOI: 10.1016/S0165-1781(01)00256-6  0.92
2001 Krystal JH, D'Souza DC, Sanacora G, Goddard AW, Charney DS. Current perspectives on the pathophysiology of schizophrenia, depression, and anxiety disorders. The Medical Clinics of North America. 85: 559-77. PMID 11349473 DOI: 10.1016/S0025-7125(05)70329-1  0.92
2001 D'Souza DC, Kosten TR. Cannabinoid antagonists: a treatment in search of an illness. Archives of General Psychiatry. 58: 330-1. PMID 11296092  0.92
2001 D'Souza DC, Krystal JH. Psychopharmacological challenge studies in psychiatric research International Review of Psychiatry. 13: 40-46.  0.92
2001 Bowers M, Boutros N, D'Souza DC, Madonick S. Substance Abuse as a Risk Factor for Schizophrenia and Related Disorders International Journal of Mental Health. 30: 33-57.  0.92
2000 D'Souza DC, Gil R, Cassello K, Morrissey K, Abi-Saab D, White J, Sturwold R, Bennett A, Karper LP, Zuzarte E, Charney DS, Krystal JH. IV glycine and oral D-cycloserine effects on plasma and CSF amino acids in healthy humans. Biological Psychiatry. 47: 450-62. PMID 10704956 DOI: 10.1016/S0006-3223(99)00133-X  0.92
2000 Laruelle M, Abi-Dargham A, van Dyck C, Gil R, D'Souza DC, Krystal J, Seibyl J, Baldwin R, Innis R. Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [(123)I]beta-CIT. Biological Psychiatry. 47: 371-9. PMID 10704949 DOI: 10.1016/S0006-3223(99)00257-7  0.92
2000 Krystal JH, Bennett A, Abi-Saab D, Belger A, Karper LP, D'Souza DC, Lipschitz D, Abi-Dargham A, Charney DS. Dissociation of ketamine effects on rule acquisition and rule implementation: possible relevance to NMDA receptor contributions to executive cognitive functions. Biological Psychiatry. 47: 137-43. PMID 10664830 DOI: 10.1016/S0006-3223(99)00097-9  0.92
1999 D'Souza DC, Berman RM, Krystal JH, Charney DS. Symptom provocation studies in psychiatric disorders: scientific value, risks, and future. Biological Psychiatry. 46: 1060-80. PMID 10536743 DOI: 10.1016/S0006-3223(99)00209-7  0.92
1999 Krystal JH, D'Souza DC, Petrakis IL, Belger A, Berman RM, Charney DS, Abi-Saab W, Madonick S. NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders. Harvard Review of Psychiatry. 7: 125-43. PMID 10483932  0.92
1999 Krystal JH, D'Souza DC, Karper LP, Bennett A, Abi-Dargham A, Abi-Saab D, Cassello K, Bowers MB, Vegso S, Heninger GR, Charney DS. Interactive effects of subanesthetic ketamine and haloperidol in healthy humans. Psychopharmacology. 145: 193-204. PMID 10463321 DOI: 10.1007/s002130051049  0.92
1999 Krystal JH, D'Souza DC, Madonick S, Petrakis IL. Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients. Schizophrenia Research. 35: S35-49. PMID 10190224 DOI: 10.1016/S0920-9964(98)00162-5  0.92
1999 Krystal JH, Belger A, D'Souza DC, Anand A, Charney DS, Aghajanian GK, Moghaddam B. Therapeutic implications of the hyperglutamatergic effects of NMDA antagonists Neuropsychopharmacology. 21: S143-S157. DOI: 10.1016/S0893-133X(99)00102-5  0.92
1998 Krystal JH, D'Souza DC. D-serine and the therapeutic challenge posed by the N-methyl-D-aspartate antagonist model of schizophrenia. Biological Psychiatry. 44: 1075-6. PMID 9836009 DOI: 10.1016/S0006-3223(98)00284-4  0.92
1998 Krystal JH, Karper LP, Bennett A, D'Souza DC, Abi-Dargham A, Morrissey K, Abi-Saab D, Bremner JD, Bowers MB, Suckow RF, Stetson P, Heninger GR, Charney DS. Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans. Psychopharmacology. 135: 213-29. PMID 9498724 DOI: 10.1007/s002130050503  0.92
1994 D'Souza DC, Bennett A, Abi-Dargham A, Krystal JH. Precipitation of a psychoneuromotor syndrome by fluoxetine in a haloperidol-treated schizophrenic patient. Journal of Clinical Psychopharmacology. 14: 361-3. PMID 7806697  0.92
Show low-probability matches.